Table 5.
Studies involving oral isotretinoin, non-melanoma skin cancer, actinic keratoses, and field cancerization
| Author, year | Study design (n): indication | Dose/duration of treatment | Results |
|---|---|---|---|
| Haydey, 1980173 | Case report (1): multiple keratoacanthomas | From 2–6 mg/kg/day, 16 weeks | No new lesions were observed |
| Peck, 19822 | Case series (3): multiple BCC | Mean of 1.5 mg/kg/day, 2.5–4 years | Regression of 9/65 lesions; no new lesions in 2–4 years |
| Levine, 1984174 | Case report (1): SCC and multiple keratoacanthomas | 2 mg/kg/day, 16 weeks | Regression of various lesions and reduction of new tumors |
| Peck, 1987191 | Case reports (2): multiple BCC | 2 mg/kg/day, 7 and 8 years | Regression of 15% of the lesions, decrease in the number of new lesions in the patient exposed to arsenic |
| Lippman, 1987175 | Case series (4): keratoacanthoma and SCC | Patient 1 – total regression of the keratoacanthoma; 2 – partial regression; 3 – partial regression of subcutaneous mass; 4–70% reduction in SCC | |
| Kraemer, 1988182 | Case series (5): xeroderma pigmentosum | 2 mg/kg/day, 2 years | 121 tumors before treatment |
| Reduction to 21 tumors in 2 years of treatment Suspension, follow-up for 1 year: 25 tumors | |||
| Peck, 1988179 | Case series (12): BCC | Mean of 3.1 mg/kg/day, 8 months | Doses of 0.25–1.5 mg/kg/day were ineffective |
| Moshell, 1989183 | Case series (5): xeroderma pigmentosum | 2 mg/kg/day, 2 years | 63% reduction in 25 tumors |
| Suspension: 8 times more tumors | |||
| Lippman, 1992187 | Series of cases (32/28): SCC | 1 mg/kg/day + interferon alfa, 2 months | Partial response: 68%; total response: 25% |
| Tangrea, 1992180 | Randomized, placebo-controlled clinical study (951): multiple SCC | 10 mg/day, 3 years | No difference with placebo |
| Majewski, 1994181 | Case series (4): multiple AK | 10.4–0.5 mg/kg/day + calcitriol, 12 months | Patient 1: complete response; 2 and 3: 50–80% regression |
| Levine, 1997190 | Randomized, placebo-controlled clinical study (525): 4 or more BCC or SCC | Retinol (25,000) × isotretinoin (5–10 mg/day) × placebo | No difference between drugs and placebo |
| Feldman, 2007172 | Case report (1): multiple keratoacanthomas | 40 mg/day, followed by acitretin and topical retinoid | Regression of some lesions |
| Troyanova, 2018171 | Case report (1): epidermodysplasia verruciformis | 0.33–1 mg/kg/day, 18 years | Reduction in the number of SCC |
| Ianhez, 2019189 | Randomized clinical study (60): AK | 10 mg/day × 0.05% tretinoin cream | Reduction in the number of AKs |
SCC, squamous cell carcinoma; BCC, basal cell carcinoma; AK, actinic keratosis.